secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001785530-26-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics Q1 net loss $13.5M; sells JZP898 to Jazz and repays K2 debt
--------------------------------------------------------------------------------

- Cash and cash equivalents $46.5M as of March 31, 2026, vs $57.1M at Dec 31, 2025.
- Net loss of $13.5M for Q1 2026, improved from $18.1M loss in Q1 2025.
- R&D expenses $8.2M (down from $13.1M YoY); G&A expenses $5.1M (up from $4.9M).
- Entered asset purchase agreement with Jazz Pharmaceuticals for JZP898 (IFNα program); repaid all K2 loan obligations as of May 6, 2026.
- Company continues to evaluate strategic alternatives with Piper Sandler; cash runway guidance to be updated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553026000011/0001785530-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553026000011/howl-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001785530-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer